大冢控股(4578.JP) 全日升4.24% 药物获FDA批准

AASTOCKS
Nov 26, 2025

大冢控股(4578.JP)今日(26日)股价收报9,027日圆,全日升4.24%。大冢制药及美国子公司宣布,“Sibrelimab”获美国FDA快速批准,用于治疗成人IgA肾症蛋白尿减少,为全球首个针对APRIL标靶药物。此前一日,公司公布注意力不足及过动症(ADHD)治疗药“Centanafadine”向FDA提交批准申请、随着抗精神病药及治疗肾病的主力药物专利到期,认为相关研发取得积极进展。...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10